Gilead wins US patent tri­al over HIV pre­ven­tion drugs

A fed­er­al ju­ry ruled in fa­vor of Gilead on Tues­day in a long-run­ning patent bat­tle over the use of its HIV drugs Tru­va­da and De­scovy for pre-ex­po­sure pro­phy­lax­is (PrEP).

While Tru­va­da and De­scovy were ini­tial­ly ap­proved for the treat­ment of HIV in 2004 and 2016, re­spec­tive­ly, they each won ap­provals years lat­er in the pre­ven­ta­tive set­ting. The US filed suit against Gilead in 2019, al­leg­ing that the com­pa­ny “ig­nored CDC’s clear con­tri­bu­tions and base­less­ly de­nied the va­lid­i­ty of CDC’s patents” in grow­ing its PrEP fran­chise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER